NeoStem does some superb analytic curve fitting

|By:, SA News Editor

NeoStem (NBS) does a retrospective pooled analysis of three melanoma clinical trials conducted from 1990 - 2011 and concludes that its Melapuldencel-T autologous immunotherapy may increase Overall Survival (OS) in patients with metastatic melanoma. Carefully parsing the data, the company finds that OS in the Melapuldencel-T cohort was 33% compared to 20% in patients treated with irradiated autologous tumor cells for the subset of patients who still had evidence of disease after prior treatment with one or more standard therapies.

Investors appear relatively unimpressed. Shares are up 3% premarket on light volume.